SecBot SecBot
PRESS-RELEASE ·Filed Apr 19, 2026

RVMD

Revolution Medicines, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The strong Phase 1 data de-risk zoldonrasib’s development and support potential accelerated approval pathways; traders should monitor for upcoming Phase 2 trial initiation or combination study readouts as next catalysts.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$146.23
T+0 close · Apr 19, 2026 · via day close
Latest settled
+26.13%
T+60 · $184.44
Vs SPY
+19.35%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 20 $146.23entry
  2. T+1 · 7mo ago +1.83%α +2.48% · $148.90
  3. T+5 · 7mo ago −9.96%α −10.87% · $131.67
  4. T+20 · 6mo ago −1.27%α −5.47% · $144.37
  5. T+60 · 4mo ago +26.13%α +19.35% · $184.44
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revolution Medicines announced updated Phase 1 data for zoldonrasib in KRAS G12D non-small cell lung cancer, showing a 52% confirmed objective response rate and 11.1-month median progression-free survival, supporting its potential as a first-in-class targeted therapy for a high-unmet-need population.

Key Facts

  • Zoldonrasib showed a 52% confirmed objective response rate (ORR) in 27 evaluable KRAS G12D NSCLC patients previously treated with immunotherapy and chemotherapy.
  • Median progression-free survival (PFS) was 11.1 months, with a 12-month PFS rate of 48%.
  • The safety profile was manageable, with Grade 3 treatment-related adverse events in 13% of patients and no Grade 4 or 5 events.
  • Data were presented at AACR 2026 and represent a key milestone in validating zoldonrasib’s clinical potential.

Financial Impact

High-value potential in a niche but significant oncology market; ~2,500 new KRAS G12D NSCLC patients annually in the U.S. and ~61,000 across all cancers.

revenuevaluationpipeline value

Risk Factors

  • Phase 1 data may not translate to later-stage success.
  • Competitive landscape could shift with other RAS inhibitors in development.
  • Regulatory path remains uncertain without Phase 3 plans yet disclosed.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3276666

US Market Status

Market Closed · Opens in 8h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 19, 2026